Rezolute, Inc.

Rezolute, Inc. is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI). The company's lead clinical asset, ersodetug, is an intravenously administered human monoclonal antibody that binds to a unique allosteric site on the insulin receptor in insulin target tissues, down modulating insulin receptor activity and helping to restore glucose to a more normalized range. Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing. The company estimates that in the U.S. alone, the initial addressable pediatric market for congenital HI is more than 1,500 individuals, and the immediately addressable incidence market for the combined indications causing tumor HI is approximately 3,000 patients in the U.S. alone per year. The company believes 60% of these tumor HI patients are managed at the National Cancer Institutes and academic medical centers, which will be the primary focus at launch.

The company faces competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies. Other companies developing therapies for HI that are potential competitors to ersodetug include Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma. The company's competitive position is supported by its intellectual property portfolio, including a worldwide, exclusive license to patents covering the ersodetug molecule, with 38 issued patents worldwide and in the U.S. (4 U.S.) and pending patent applications with claims directed to compositions of matter and methods of use in therapy, expiring between 2030 and 2036. The company also expects to have further exclusivity in the form of data and marketing exclusivity under pharmaceutical regulatory laws, including potentially up to 12 years of exclusivity from the date of first BLA approval.

Rezolute generates revenue through the development and potential commercialization of its product candidates, primarily ersodetug, for the treatment of hyperinsulinism. The company has not yet generated any product revenue, as its product candidates are in clinical development. The company's business model relies on obtaining regulatory approvals and commercializing its therapies, either independently or through strategic partnerships. The company also maintains an expanded access program (EAP) for a variety of HI indications, making ersodetug available on a compassionate use basis when patients have refractory hypoglycemia and cannot access a clinical trial.

Ersodetug is being developed for the treatment of congenital HI and tumor HI. For congenital HI, the sunRIZE Phase 3 study did not meet its primary endpoint (hypoglycemia events by finger stick self-monitored blood glucose) or its key secondary endpoint (time in hypoglycemia by continuous glucose monitoring) at the defined Week 24 evaluable window. However, larger and often nominally statistically significant reductions in hypoglycemia compared to placebo were consistently observed throughout the maintenance dosing phase, across time and numerous pre-specified and post-hoc CGM-based endpoints. The company met with the FDA on March 17, 2026, under its Breakthrough Therapy Designation to discuss next steps, and the FDA encouraged the company to submit comprehensive analysis datasets and summary outcomes for the Agency's independent evaluation. All 59 participants who completed the study elected to continue to receive ersodetug in the open-label extension (OLE), with 56 participants remaining as of the filing date, with exposure durations ranging from ~9 months to more than 24 months.

For tumor HI, the company initiated the Phase 3 registrational study (upLIFT) in mid-2025, a streamlined single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or paraneoplastic non-islet cell tumors who require continuous parenteral dextrose. The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in the rate of continuous parenteral dextrose (glucose infusion rate; GIR), with statistical significance achieved if the lower bound of the 95% confidence interval of the point estimate exceeds 30% (equating to a responder rate of ~9 of 16 participants). On June 2, 2026, the company provided an interim update based on the initial 8 participants, of which six had already met the responder criterion, and each of these 6 participants also achieved a complete discontinuation of intravenous glucose requirements. Since that announcement, the seventh participant has also met the responder criterion, while the eighth participant withdrew consent and was counted as a non-responder. The company anticipates completing enrollment and announcing topline results from the study before the end of 2026.

The company maintains an expanded access program (EAP) for a variety of HI indications. In the EAP for tumor HI, 75% of the patients receiving IV dextrose/total parenteral nutrition achieved a complete discontinuation of IV dextrose/TPN. The company has received numerous inbound physician inquiries regarding the use of ersodetug in patients with tumor HI, leading to compassionate use treatment in more than a dozen patients. In the EAP for congenital and other forms of hyperinsulinism, the duration of treatment ranges from more than a year to more than 4 years, with ongoing benefit. The company also has a workforce of 58 full-time employees as of June 30, 2026, with 40 engaged in research and development and 18 in general and administrative functions.

For the fiscal years ended June 30, 2026 and 2025, the company incurred approximately $53.8 million and $61.5 million in research and development expenses, respectively. The company is a non-accelerated filer and a smaller reporting company. As of December 31, 2025, the aggregate market value of the company's voting stock held by non-affiliates was approximately $203,924,000, based on the last reported sales price of $2.36 as quoted on the Nasdaq Capital Market. The company had 96,722,333 shares of its $0.001 par value common stock outstanding as of September 21, 2026.

However, the company anticipates completing enrollment and announcing topline results from the upLIFT study before the end of 2026. The company is also evaluating the appropriate timing to conclude the sunRIZE study OLE and move patients into its EAP, depending in part on outcomes from pending FDA interactions.

The primary growth vector for the company is the advancement of ersodetug through clinical development and regulatory approval for congenital HI and tumor HI. For congenital HI, the company is awaiting FDA feedback on the supplemental information submitted for the Agency's independent evaluation, with the potential for a determination on whether there is sufficient evidence to support the submission of a marketing application for sunRIZE or if additional information and/or clinical studies are required. For tumor HI, the upLIFT study is a streamlined Phase 3 registrational trial, and the company remains cautiously optimistic regarding the probability of success based on historical precedent, supportive data from the sunRIZE study, the recent liberalization of the tumor HI study, and the experience reported in the historical Expanded Access Program.

The company is also pursuing the expanded access program (EAP) as a growth vector, making ersodetug available on a compassionate use basis for patients with refractory hypoglycemia who cannot access a clinical trial. The EAP has served to provide access to patients with tumor HI and congenital HI, with some patients treated for more than 2 years in the tumor HI subset and more than 4 years in the congenital HI subset. The company believes the unique mechanism of action of ersodetug makes the therapy a potential universal treatment for any form of HI, which could expand its addressable market beyond the initial estimates of more than 1,500 individuals for congenital HI and approximately 3,000 patients per year for tumor HI in the U.S.

The company's margin and cost outlook is not explicitly detailed in the filing, but the company's research and development expenses decreased from approximately $61.5 million in fiscal year 2025 to approximately $53.8 million in fiscal year 2026. The company's operating plans and cash resources may be impacted by the FDA's review of the sunRIZE data, as additional information or clinical studies could be required, which could change the scope, timeline, and required resources of the company's operations.

The company's operational outlook includes its reliance on third-party manufacturers or strategic partners to manufacture its pharmaceutical drugs and diagnostics that receive regulatory approval. The company also relies primarily on third parties to conduct its clinical trials, which may result in less control over the timing, conduct, and expense of these trials. The company has 58 full-time employees as of June 30, 2026, all located in the United States, and none are covered by a collective bargaining agreement.

The company's capital allocation strategy is focused on funding its research and development activities, with approximately $53.8 million and $61.5 million in R&D expenses for fiscal years 2026 and 2025, respectively. The company has not declared any dividends, and its capital allocation priorities are centered on advancing its clinical programs and maintaining liquidity. The company's cash position and ability to obtain additional financing are critical to its operations, as it expects to continue incurring significant expenses related to clinical development.

A significant headwind is the uncertainty surrounding the FDA's review of the sunRIZE data for congenital HI. The FDA has not provided a specific timeline for feedback, and there is no guarantee that the Agency will agree to a viable path forward. If the company is required to conduct a new randomized study or provide additional information, its operational plans may change significantly, potentially requiring substantial additional resources. Additionally, the FDA may consider the results of the sunRIZE trial when assessing the upLIFT trial results, which could impact the company's business and future plans.

Another headwind is the inherent risk of clinical trial failure, as the sunRIZE trial failed to meet its primary and key secondary endpoints. The company's preclinical studies and early clinical trials may not be predictive of later-stage results, and positive results from earlier trials may not be replicated. The company also faces risks related to regulatory approval, including potential delays or rejections based on changes in regulatory authority policies, and the need to demonstrate safety and efficacy in well-controlled studies.

The company faces significant regulatory and clinical risks. The FDA's review of the supplemental information for ersodetug in congenital HI may not result in a viable path forward, and the company could be required to conduct a new randomized study, which would significantly change its operational plans and cash resources. The sunRIZE trial failed to meet its primary and key secondary endpoints, and there is no guarantee that the FDA will not consider these results when evaluating the upLIFT trial for tumor HI, which could delay or prevent approval. The upLIFT trial, despite modifications, may fail to produce effective results, and the company's interim data, with six of eight participants meeting the responder criterion, may not be replicated in the final analysis. The company's reliance on third parties to conduct clinical trials and manufacture its product candidates introduces risks related to timing, quality, and regulatory compliance. Additionally, the company's product candidates may produce serious adverse events, which could interrupt, delay, or halt clinical trials and prevent regulatory approval. The company has not yet obtained regulatory approval for any product candidate, and the process is expensive and uncertain, with no guarantee of success.

Management's message to shareholders emphasizes the company's position as a late-stage rare disease company focused on developing therapies for hyperinsulinism, with a lead asset, ersodetug, that has the potential to be universally effective at treating hypoglycemia related to HI. The tone is cautiously optimistic, acknowledging the sunRIZE trial's failure to meet its primary and key secondary endpoints but highlighting the consistent improvements in CGM-based endpoints and the pharmacologic activity observed. Management emphasizes the FDA's acknowledgment of the challenges posed by behavioral factors in clinical trials for this patient population and the Agency's encouragement to submit comprehensive analysis datasets for independent evaluation. The strategic priorities for the period ahead include advancing the upLIFT Phase 3 study for tumor HI, with an anticipated completion of enrollment and topline results before the end of 2026, and awaiting FDA feedback on the path forward for congenital HI. Management also highlights the positive interim data from the upLIFT study, with six of the initial eight participants meeting the responder criterion, and the continued benefit observed in the expanded access program.